The US Food and Drug Administration (FDA) approved immunotherapy for unresectable or metastatic solid tumors with PD-L1 expression [11], mismatch repair deficiency (dMMR) or microsatellite instability (MSI) [12], or high tumor mutational burden (TMB) [13]. Here, CD274 is linked to neoplasm.